Literature DB >> 17576158

Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors.

Karine Breckpot1, Perpetua Emeagi, Melissa Dullaers, Annelies Michiels, Carlo Heirman, Kris Thielemans.   

Abstract

Dendritic cells (DCs) are an attractive tool for immunomodulation, targeting mature DCs (mDCs) for immunization or immature/semimature DCs (iDCs) for tolerization. Therefore, introducing antigens into DCs has become a prime topic in various immunological disciplines. Numerous studies have shown that lentiviruses are an efficient vehicle for this purpose. This study evaluates the effects of lentiviral transduction on iDC activation. Immature DCs are efficiently transduced with increasing doses of lentivirus without affecting cell viability. Transduction at low multiplicities of infection (MOIs) did not result in phenotypical or functional maturation. Higher doses of lentivirus, however, resulted in upregulation of adhesion, costimulatory, and HLA molecules, as well as in increased allostimulatory capacity and secretion of interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha. Production of IL-12 p70, IL-10, and interferon-alpha was observed only at extremely high doses. Protein kinase R phosphorylation on transduction at an MOI of 150 was demonstrated by Western blotting. A Toll-like receptor (TLR)-driven luciferase reporter assay showed dose-dependent activation of TLR2, TLR3, and TLR8, which was independent of the pseudotype, production, or transduction protocol and was abrogated on heat inactivation. These data show that lentiviral vectors provide not only the antigen but also appropriate activation signals to iDCs, favoring their use for immunotherapy and vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576158     DOI: 10.1089/hum.2007.006

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  21 in total

1.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

2.  Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.

Authors:  Jocelyn T Kim; Yarong Liu; Rajan P Kulkarni; Kevin K Lee; Bingbing Dai; Geoffrey Lovely; Yong Ouyang; Pin Wang; Lili Yang; David Baltimore
Journal:  Sci Immunol       Date:  2017-07-21

3.  Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.

Authors:  C Goyvaerts; Y De Vlaeminck; D Escors; S Lienenklaus; M Keyaerts; G Raes; K Breckpot
Journal:  Gene Ther       Date:  2017-05-25       Impact factor: 5.250

4.  Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells.

Authors:  J-M Humbert; C Frecha; F Amirache Bouafia; T H N'Guyen; S Boni; F-L Cosset; E Verhoeyen; F Halary
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 5.  Lentiviral vectors in gene therapy: their current status and future potential.

Authors:  David Escors; Karine Breckpot
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02-09       Impact factor: 4.291

6.  HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

Authors:  Karine Breckpot; David Escors; Frederick Arce; Lucienne Lopes; Katarzyna Karwacz; Sandra Van Lint; Marleen Keyaerts; Mary Collins
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

7.  Tailored HIV-1 vectors for genetic modification of primary human dendritic cells and monocytes.

Authors:  Stéphanie Durand; Xuan-Nhi Nguyen; Jocelyn Turpin; Stephanie Cordeil; Nicolas Nazaret; Séverine Croze; Renaud Mahieux; Joël Lachuer; Catherine Legras-Lachuer; Andrea Cimarelli
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

Review 8.  Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

Authors:  Karine Breckpot; David Escors
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2009-12       Impact factor: 2.895

9.  Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization.

Authors:  Frederick Arce; Helen M Rowe; Benjamin Chain; Luciene Lopes; Mary K Collins
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

10.  Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing.

Authors:  Qiuwei Pan; Scot D Henry; Herold J Metselaar; Bob Scholte; Jaap Kwekkeboom; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  J Mol Med (Berl)       Date:  2009-04-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.